View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 28, 2022

Two booster trials to evaluate Novavax’s protein-based Covid-19 vaccine

The NVX-CoV2373 vaccine will be assessed as a booster in a NIAID-sponsored Phase I/II trial and a Phase III trial in the UAE.

Novavax has reported that its protein-based Covid-19 vaccine, NVX-CoV2373, will be included in two clinical trials to analyse it as a booster.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Created from the initial strain of the SARS-CoV-2 virus’ genetic sequence, the vaccine has a purified protein antigen.

Furthermore, it is formulated with a saponin-based Matrix-M adjuvant of the company to boost immune response and induce increased neutralising antibody levels.

The ongoing studies have initiated subject enrolment and will analyse the safety, immunogenicity and reactogenicity of the vaccine.

They are intended to expand knowledge of how various vaccines, including Novavax’s NVX-CoV2373, can be used for boosting after an initial vaccine regimen.

A National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Phase I/II trial is underway to evaluate homologous and heterologous boosting regimens in subjects who have previously received a primary vaccine regimen.

The vaccines used in the initial vaccine series have obtained approval or emergency use authorization (EUA) from the US Food and Drug Administration (FDA).

In this trial, subjects will receive a third dose of either NVX-CoV2373 or any of the three FDA-authorised or -approved Covid-19 vaccines after more than 12 weeks.

Carried out at around ten study centres, the trial will have approximately 1,130 healthy subjects aged 18 years or above, with nearly 180 of them receiving the Novavax vaccine as a heterologous booster.

Assessing the safety, reactogenicity and immunogenicity of delayed heterologous or homologous vaccine doses following EUA vaccines are the primary objectives of the trial.

Subjects will be followed up for a year and topline data and full findings from the trial are anticipated later this year and next year, respectively.

The second study of Novavax’s vaccine, being carried out in the United Arab Emirates (UAE), is an observer-blinded Phase III trial.

It will analyse homologous versus heterologous boosting of subjects previously vaccinated with Sinopharm’s Covid-19 vaccine.

In this study, safety and immunogenicity following boosting with a single dose of Novavax’s vaccine in previously inoculated adults will be studied. 

It will enrol nearly 1,000 subjects of age 18 years or above at two sites in Abu Dhabi, UAE, who will be followed up for six months.

Full data from this trial is expected in the fourth quarter of this year. 

Novavax chief medical officer Filip Dubovsky said: “Our Covid-19 vaccine has already been recommended by multiple national policy bodies for both primary vaccination and booster settings in individuals 18 years of age and older.

“We look forward to adding to this body of evidence to support the expanded use of our protein-based vaccine.”

In February, the company reported that NVX-CoV2373 met the primary immunogenicity endpoint in the paediatric expansion of its Phase III PREVENT-19 trial.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena